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stimulates platelets, endothelial cells, and other impor-
tant constituents of blood coagulation.2 Heparin directly
inhibits circulating thrombin and partially inhibits
thrombin formation by weakly inhibiting factor Xa and
factor IXa3; it inhibits thrombin activity within blood
clots only at very high concentrations.4 Inhibition of
thrombin formation, as opposed to inhibition of throm-
bin after it is formed, offers the prospect of down-regu-
lating the overall coagulation stimulus during cardiac
operations and surmounting disadvantages of unfrac-
tionated heparin. 
The intrinsic and extrinsic coagulation pathways con-
verge by converting factor X to factor Xa, which initi-
ates formation of the prothrombinase complex and con-
verts prothrombin to thrombin.2,5 Several peptides,
found in leeches and spiders, bind factor Xa in nanomo-
lar concentrations,6 but recombinant forms of these pro-
teins fail to suppress thrombin formation during in vitro
extracorporeal perfusion.7 Compared with standard
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heparin, low molecular weight heparins are more
potent inhibitors of factor Xa in vivo8 and better sup-
pressors of thrombin generation in patients with deep
venous thrombosis.9 Low molecular weight heparin has
also been used for clinical cardiac operations.10-12
In a previous study we observed that the low molecu-
lar weight heparin, enoxaparin, completely suppressed
complement activation and neutrophil elastase release
during in vitro, simulated, extracorporeal recirculation
of fresh human blood.7 The same study also showed that
thrombin formation and activity, as measured by the
generation of the prothrombin fragment F1.2 and fib-
rinopeptide A, was attenuated by enoxaparin as com-
pared with standard porcine heparin.7 The present in
vivo study tests the hypothesis that anticoagulation with
enoxaparin or a combination of enoxaparin and standard
heparin attenuates thrombin formation and activity and
also reduces complement formation and neutrophil elas-
tase release during CPB in baboons. 
Methods
Preliminary in vitro studies. Enoxaparin (Clexane;
Rhone-Poulenc Rorer, Vitry Sue Seine, France) is a depoly-
merized heparin with a molecular mass of 3500 to 5500 kD.
In blood from 3 baboons, 12 enoxaparin concentrations
between 0 and 1500 U/mL (approximately 1 mg = 100 IU
anti-factor Xa activity) were titrated against activated clotting
times to determine the dose required to increase the activated
clotting time to just over 600 seconds. This dose (10 U/mL)
was used to calculate the enoxaparin dose for in vivo studies. 
In 3 baboons, the dose of enoxaparin was given intra-
venously (blood volume assumed 0.08 times body weight) to
raise the activated clotting time to 625 ± 70 seconds. Sixty
minutes later, the activated clotting time was 353 ± 13 sec-
onds. Ten and 60 minutes after protamine (4 mg/100 U
enoxaparin), activated clotting times were 195 ± 4 and 147 ±
9 seconds, respectively.
The effects of standard porcine intestinal heparin and enoxa-
parin on complement C1-s and factor Xa inhibition in human
and baboon blood were compared. Fresh human (n = 2) and
baboon (n = 2) peripheral venous blood was drawn directly into
test tubes containing 3 different anticoagulants: porcine
heparin (3.75 U/mL), enoxaparin (17.5 U/mL), and 3.8% sodi-
um citrate (10% citrate/90% blood by volume). Blood was cen-
trifuged at 2000g for 20 minutes; the supernatant was further
centrifuged at 15,000g for 10 minutes; this supernatant was
divided into aliquots and stored at –80°C until studied. For
analysis aliquots (12.5 m L) of plasma were incubated with 100
m L of 0.1 U/mL FXa (Enzyme Research Laboratories Inc,
Southbend, Ind) in microtitre plate wells and incubated for dif-
ferent time intervals (0 to 10 min). Chromogenic substrate S-
2222 (Chromogenix, Franklin, Ohio) was added and
absorbance was read at 405 nm after 12 minutes. 
For C1-s inhibition plasma or phosphate-buffered saline
solution (PBS; 0.1 mol/L containing 0.15 NaCl, pH 7.4) and
substrate, S2314 (Chromogenix) were preincubated at 37°C
for 2 minutes. Activated human C1-s (1.0 m mol/L, final con-
centration; Enzyme Research Laboratories Inc) was added to
yield a total volume of 200 m L and incubated at 37°C in a water
bath. The final concentration of S2314 was 0.5 mol/L. The
reaction was stopped at 0, 5, 10, and 30 minutes by adding 100
m L 50% (vol/vol) acetic acid. Triplicate samples (80 m L) were
placed in a disposable nonsterile assay plate (96 well; Corning,
Inc, Corning, NY) and measured at 405 nm by the enzyme-
linked immunosorbant assay reader (Multiscan Biochromatic
Plate Liter; ICN Pharmaceuticals, Huntsville, Ala).
In vivo studies. Thirteen juvenile baboons (Papio annubis)
weighing 10 to 23 kg were used. The animals were divided
into 3 groups: standard procine intestinal heparin (300 U/kg;
Elkins-Sinn, Inc, Cherry Hill, NJ) control (group 1, n = 10);
enoxaparin (800 U/kg; group 2, n = 8); and a combination of
porcine heparin (225 U/kg) and enoxaparin (200 U/kg; group
3, n = 9). Baboons were studied when the mandated rest peri-
od of 6 to 8 weeks between studies expired or when new ani-
mals completed quarantine; 3 animals were studied thrice; 8
animals, twice; and 2 animals, once. Activated clotting times
with the use of kaolin were monitored throughout the study,
and all times increased over 500 sec with each bolus dose of
anticoagulant. This study was approved by the University of
Pennsylvania Committee on Animal Care and Utilization
(IACUC). 
For each CPB experiment, the baboon was placed in a
squeeze cage, sedated with 10 mg/kg ketamine hydrochloride
intramuscularly, and induced with 5 mg/kg thiopental sodium
intravenously. The animal was intubated; general anesthesia
was maintained with inhalational isofluorane. The right or
left side of the neck and both groins were prepared and
draped appropriately for sterile cutdown and cannulation of
vessels. Hemodynamic monitoring was accomplished with an
arterial line with a 22-gauge catheter placed in the femoral
artery, and a 5F balloon-tipped pulmonary artery catheter
placed via a femoral vein. After anticoagulation, a 10F to 14F
Bio-Medicus (Medtronic Bio-Medicus, Eden Prairie, Minn)
wire-wrapped, polyurethane catheter was introduced into the
jugular vein and advanced into the right atrium. A similar, but
shorter 8F, arterial catheter for reinfusion was inserted into
the femoral artery.
Each bypass circuit was assembled with silicone-rubber
tubing (Dow Corning Corporation, Midland, Mich), incorporat-
ing a bubble oxygenator (Bentley 5/Pediatric; Baxter Health-
care, Inc, Irvine, Calif), an arterial filter (Intersept Pediatric;
Medtronic, Inc, Anaheim, Calif), and a roller pump (model
13400; Sarns/3M, Ann Arbor, Mich).13 The circuit was
primed with approximately 500 mL of Normosol solution
(Abbott Laboratories, North Chicago, Ill). Normothermic CPB
began at a flow rate of 50 mL/kg/min (approximately one half
of the baboon’s resting cardiac output), and perfusion was
maintained for 60 minutes. Ten minutes after CPB ended,
protamine was given for total doses of anticoagulant as fol-
lows: 1 mg/100 U heparin; 4 mg/100 U enoxaparin.
Sampling times. Six blood samples (15 to 20 mL each)
were obtained at baseline before anticoagulation (time-point
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labeled BASELINE); after anticoagulation (HEPARIN); 5
minutes after starting CPB (START); 5 minutes before stop-
ping CPB (END); 10 minutes after protamine (3 mg/kg;
Elkins-Sinn, Inc, Cherry Hill, NJ) (PROTAMINE); and 60
minutes after time-point PROTAMINE (PROTAMINE-60).
Some additional hematologic measurements were made 120
and 180 minutes after protamine and 24 hours later. 
Measurements. Heart rate by electrocardiogram, systemic
(systolic, diastolic, mean) arterial blood pressures, central
venous pressure, pulmonary arterial pressure, and pulmonary
capillary wedge pressure were continuously monitored.
Intermittent thermodilution cardiac outputs were measured in
duplicate before and after CPB. Blood samples were assayed
for hematocrit, platelet count, white blood cell count, platelet
aggregation to adenosine diphosphate (ADP), b -thromboglob-
ulin (b TG) release, release of neutrophil elastase, complement
glycoproteins C3b/c and C4b/c, prothrombin fragment F1.2,
thrombin-antithrombin complex (TAT), and fibrinopeptide A
(FPA). Template bleeding times were measured at 6 time
points. Dilution of formed blood elements and plasma proteins
were corrected with the use of hematocrit. The total amount of
blood withdrawn was limited to less than 10% of body weight
(120 to 180 mL) for each experiment, and blood remaining in
the perfusion circuit was reinfused at the end of CPB. 
Hematocrit and platelet count assays were performed on
whole blood. Platelets were counted by phase microscopy or
by Coulter Counter (model STKR; Coulter Electronics Inc,
Hileah, Fla) in triplicate. After correction for hemodilution,
platelet counts were expressed as a percentage of BASELINE
values. Platelet aggregation to ADP was studied with a Payton
aggregometer (model 440; Chrono-Log, Inc, Havertown, Pa).
Platelet-rich plasma and platelet-poor plasma were prepared
from citrated blood (10 mL with 10% by volume of 3.8% cit-
rate) by differential centrifugation at 150g for 10 minutes and
13,600g for 5 minutes, respectively. Before studies of aggre-
gation, the platelet count of platelet-rich plasma was adjusted
to 150,000/ m L by dilution with platelet-poor plasma. The
concentration of ADP required to produce complete second-
wave aggregation was measured; complete second-wave
aggregation was assumed when light transmission was 62.5%
or greater within 5 minutes.14 Platelet aggregation is reported
as a percentage and normalized to the concentration of ADP
required to obtain full aggregation of the baseline sample.
The percent aggregation observed at that ADP concentration
in subsequent samples is recorded.
Template bleeding times were measured in duplicate on the
forearm at the same time points as blood samples, except dur-
ing CPB, and were measured 120 and 180 minutes and 24
hours after PROTAMINE (time points labeled PROTAMINE-
120, PROTAMINE-180, and 24 hours) with a blood-pressure
cuff inflated to 40 mm Hg. The Simplate II (Organon Teknika
Corporation, Durham, NC) lancet was used to create repro-
ducible skin incisions for determinations of bleeding times.
For plasma b -TG analysis blood was withdrawn into cen-
trifugation tubes containing 10% (by volume) of 3.8% acid
citrate dextrose and prostaglandin E1 solution at 0°C. b -TG
was measured by radioimmunoassay.15
Measurements of complement activation in baboon blood
is difficult because of poor cross-reactivity with human anti-
bodies.16,17 Assays for C3b/c and C4b/c have been developed
and used successfully in studies of sepsis.16,17 C3b/c levels
were assessed by radioimmunoassay with a monoclonal anti-
C3-28 antibody and a polyclonal 125I-anti-C3c antibody.16
C4b/c was measured by a radioimmunoassay similar to that
used for the determination of C3b/c, except that a monoclon-
al anti-C4-1 antibody and a polyclonal 125I-anti-C4 antibody
were used.17 Both C3b/c and C4b/c results were expressed as
a percentage of the amount of C3b/c or C4b/c present in nor-
mal baboon serum. 
Elastase-a 1 proteinase inhibitor levels were measured by 2
different enzyme-linked immunosorbent assay (ELISA) meth-
ods. The first assay (elastase-a 1 proteinase inhibitor) was per-
formed with commercial kits that used a polyclonal antibody
to elastase as a capture antibody and conjugation with a anti-
body to a 1-proteinase inhibitor complexed with alkaline phos-
phatase (Merck Immunoassay; Merck Inc, West Point, Pa).
The second assay (elastase-a 1-antitrypsin) used 2 monoclonal
antibodies; one against elastase complexed with sephadex
beads and another against a 1-antitrypsin labeled by 125I.18
Plasma levels of F1.2 (Behring Diagnostics, Inc, Westwood,
Mass),19 FPA (American Bioproducts, Parsipanny, NJ),20
TAT (Behring Diagnostics, Inc)21 were measured by ELISA
with commercial assay kits. 
Statistics. Data points represent the mean ± SEM of mea-
surements. Three-way analysis of variance (MANOVA) for
repeated measures with the Bonferroni adjustment (SPSS for
Windows 7.5; SPSS Inc, Chicago, Ill) was used for statistical
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Fig 1. Comparison of anti-factor Xa activity in human and
baboon plasma anticoagulated with 3.8% sodium citrate,
heparin (3.75 U/mL) or enoxaparin (17.5 U/mL). At 10 min-
utes incubation, heparin and enoxaparin inhibited FXa equally;
however, inhibition by heparin and enoxaparin was greater in
baboon plasma than human plasma. Open symbols represent
human plasma; solid symbols, baboon; squares, citrate; cir-
cles, heparin; triangles, enoxaparin.
analysis of time and group effects. When group effects were
significant (P < .05), 2-way ANOVA between control and
both enoxaparin groups (separately) was used to establish
significant differences (P < .05) between the control group
and each experimental group. The unpaired t statistic was
used for specific comparisons between groups when the 2-
way ANOVA group effect was significant. The paired Student
t test with Bonferroni correction was used for analysis of dif-
ferences within groups when the time effect was significant
by 3-way MANOVA and 1-way ANOVA. Differences were
considered statistically significant at the P < .05 level.
Results
Preliminary in vitro study. Both heparin and enoxa-
parin inhibited FXa as compared with citrate, even at
the first sampling time. The inhibition at 0 time was
greater with enoxaparin than heparin, but there was no
difference in residual FXa activity at 10 minutes be-
tween anticoagulants for either human or baboon plas-
ma. However, inhibition of FXa for both heparin and
enoxaparin was greater in baboon plasma as compared
with human plasma at nearly all time points (Fig 1).
This indicates that both heparin and enoxaparin are
more effective inhibitors of FXa in baboons than in
human beings. 
Both heparin and enoxaparin inhibited C1-s more
than citrate, and there was no difference in the degree
of inhibition between human and baboon plasma for
enoxaparin. However, heparin produced greater inhibi-
tion of C1-s in human plasma than in baboon plasma
after 10 minutes of incubation (data not shown). 
In vivo studies. There were no significant differ-
ences between groups for arterial blood pressure, cen-
tral venous pressure, pulmonary arterial and capillary
wedge pressures, or cardiac output at any time point.
During CPB, activated clotting times remained higher
than 400 seconds for all animals (Table I). For 3 hours
after protamine, activated clotting times remained sig-
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Table I. Means and standard error of the means
3-Way MANOVA
Protamine- Protamine- Protamine 24- Drug 
Baseline Heparin Start End Protamine 60 120 180 hours Drug Time time*
Hematocrit (%)
Control 32.1±0.6 31.5±0.9 16.8±0.6† 20.3±0.7† 25.6±0.71† 26.4.2±0.8† 26.2±1.0† 25.9±1.0† 25.8±1.1†
Enoxaparin 33.0±0.4 32.2±0.5 18.7±0.8†‡ 21.6±0.5† 27.1±0.6† 26.8±0.6† 26.4±0.5† 27±1† 19.6±1.4‡ .019 .000 .029
Hep+Enox 31.3±0.5 30.7±0.6 16.6±0.5† 20.1±0.6† 24.8±0.9† 25.5±0.5† 26.6±1.0† 25.7±0.7† 22.6±0.9‡
ACT (sec)
Control 111.3±3.4 608.3±41.7† 679.8±42.5† 477.8±39.0† 119.6±3.0 126.8±5.1 125.4±4.2 125.1±4.3 122.2±8.3
Enoxaparin 110.6±4.0 583.9±85.7† 520.8±27.4† 425.2±17.2† 228.8±8.8‡ 183.9±3.3‡ 173.3±9.0‡ 175.2±6.4‡ 125.5±9.3 .834 .000 .030
Hep+enox 124.4±4.3 563.9±62.8† 627.8±40.2† 465.2±37.0† 163.2±7.9‡ 164.1±8.5‡ 162.5±7.6‡ 169.8±11.1‡ 132.0±3.8
Platelet count (% of baseline)
Control 100 95.4±2.4 89.9±4.8 62.7±7.3† 47.9±4.6† 51.3±5.6† 40.5±6.0† 39.8±7.1† 57.6±7.0†
Enoxaparin 100 100.1±6.9 92.1±7.2 66.4±6.2† 23.3±1.6†‡ 44.6±6.0† 39.9±3.2† 43.2±3.6† 74.9±5.6 .506 .000 .005
Hep+enox 100 88.7±2.7 79.7±3.4‡ 49.3±4.7† 36.6±3.5†‡ 44.6±4.2† 45.4±4.8† 47.8±5.5† 74.8±5.4†
Aggregation to ADP (% of baseline)
Control 100 107.6±4.5 70.2±9.7 61.1±9.1† 59.0±8.9† 59.6±7.8†
Enoxaparin 100 104.6±2.7 69.7±4.5† 65.1±7.2† 41.9±5.5† 53.4±5.3† .571 .000 .737
Hep+enox 100 115.4±6.6 72.4±6.8† 53.2±7.1† 46±5.8† 55.6±7.0†
b -TG (ng/mL)
Control 23.1±6.7 20.4±3.3 54.9±10.5 159.0±12.8 66.5±8.8† 34.2±9.2
Enoxaparin 37.0±11.1 29.4±2.3 72.6±13.7 163.6±11.1† 137.0±11.7†‡ 72.7±12.8‡ .000 .000 .045
Hep+enox 10.6±3.6 24.8±6.7 74.6±13.9 167.2±18.5 74.9±14.6 28.4±6.9
Bleeding (min)
Control 4.2±0.2 6.4±0.6 17.6±1.4† 15.2±1.4† 11.4±1.2† 11.2±1.4† 6.6±1.5
Enoxaparin 3.8±0.2 6.2±0.4 20† 20†‡ 14.2±1.4† 15.2±1.5† 13.6±2.2†‡ .000 .000 .113
Hep+enox 3.8±0.1 7.9±0.5 18.1±1.3 16.8±0.1† 15.1±1.5† 14.7±1.8† 8.8±1.7
WBC count (% of baseline)
Control 100 108.7±3.5 91.8±14.8 254.9±26.3† 208.0±14.0† 309.0±16.5† 328.1±25.7† 312.0±31.2† 382.7±43.9
Enoxaparin 100 107.9±4.7 122.7±31.9 310.1±66.4 300.7±53.9 376.7±54.2† 388.2±54.9† 389.3±57.5† 567.2±86.7 .001 .000 .676
Hep+enox 100 113.8±10.3 87.4±8.3 217.4±25.2 180.9±30.0 327.8±32.6† 359.6±36.2† 349.9±39.7† 490.9±56.2
ACT, Activated clotting time; Hep, heparin; enox, enoxaparin; WBC, white blood count. P values are given for 3-way MANOVA with Bonferroni adjustment for
repeated measures.
†P < .05, within group t statistic with Bonferroni correction, compared with baseline.
‡P < .05, between groups, statistic with Student unpaired t test compared with control value when 2-way ANOVA group effect is P < .05.
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Fig 2. Platelet counts before, during, and after CPB. Platelet counts are corrected for hemaocrit and presented as
percentage of baseline (before heparin) values. Data presented as mean ± SEM. Open squares represent heparin
group; diamonds, enoxaparin group; closed squares, combination group. 
Table II. Means and standard error of the means
3-Way MANOVA
Baseline Heparin Start End Protamine Protamine-60 Drug Time Drug time
Neutrophil elastase (m L)
Control 77.5±4.9 80.1±6.6 146.2±10.3† 145.7±10.3 111.4±9.5 111.6±8.6
Enoxaparin 95.4±4.6‡ 93.0±4.8 155.6±9.7† 154.2±7.5 132.4±5.5† 126.5±4.9† .000 .000 .653
Hep+ enox 70.6±3.0 86.9±12.9 116.2±4.8†‡ 131.6±9.7 112.3±10.1† 104.6±8.1
c3b/c (% of normal plasma amt)
Control 1.28±0.13 1.35±0.27 5.70±0.58 22.77±4.03† 26.13±7.07† 19.41±4.39†
Enoxaparin 1.51±0.22 1.27±0.17 4.81±0.41 17.29±2.79† 14.53±1.82† 12.04±1.13† .004 .000 .238
Hep+enox 0.78.±0.12‡ 0.86±0.14 9.28±2.05 32.11±6.31† 25.43±3.84† 19.98±2.77†
c4b/c (% of normal plasma amt)
Control 2.28±0.29 2.06±0.25 2.93±0.29 5.46±0.34 13.43±6.24 11.85±5.20
Enoxaparin 3.41±0.68 1.84±0.44 2.25±0.38 4.47±0.88 5.73±1.20 5.99±1.10 .181 .000 .673
Hep+enox 1.82±0.37 1.79±0.47 3.38±0.64 7.85±2.2 8.95±1.86† 9.3±1.86†
FPA (ng/mL)
Control 6.15±0.70 2.79±0.41 4.24±1.17 11.45±3.74 5.84±0.99 6.91±3.12
Enoxaparin 8.91±1.35 2.01±0.35† 2.01±0.45† 1.52±0.17†‡ 28.66±1.27†‡ 1.66±0.13† .006 .000 .000
Hep+enox 8.34±2.43 3.11±1.2 2.92±0.59 4.66±1.28 5.76±1.41 1.27±0.29†
F1.2 (nmol/L)
Control 1.03±0.09 1.15±0.15 1.18±0.17 3.20±0.48† 2.79±0.41† 2.41±0.37†
Enoxaparin 1.01±0.06 0.92±0.07 0.83±0.10 1.03±0.19‡ 1.57±0.26‡ 1.46±0.18‡ .000 .000 .000
Hep+enox 1.09±0.16 1.34±0.20 1.34±0.24 2.37±0.31† 1.88±0.26 1.49±0.21‡
TAT (mg/L)
Control 8.27±1.62 12.96±4.0 9.53±2.16 73.62±7.27† 44.70±5.42† 33.11±5.58†
Enoxaparin 9.39±1.68 7.38±0.79 6.38±0.83 16.97±4.28‡ 19.72±2.45†‡ 13.54±1.67‡ .000 .000 .000
Hep+enox 7.21±2.21 8.92±1.12 9.19±1.62 45.37±12.14†‡ 25.4±5.75‡ 15.52±3.53‡
See Table I for an explanation of P values and symbols.
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Fig 3. Blood prothrombin fragment (F1.2) before, during, and after CPB. Values are corrected for hematocrit. See
Fig 2 for an explanation of the symbols.
Fig 4. Plasma thrombin-antithrombin complex before, during, and after CPB. Values are corrected for hematocrit.
See Fig 2 for an explanation of the symbols.
nificantly elevated in both the enoxaparin and combi-
nation groups as compared with control animals but
were similar at 24 hours (Table I).
Platelet counts did not differ between groups during
CPB but were significantly lower than control in both
groups that received enoxaparin at the time protamine
was given, but not thereafter (Fig 2). The type of antico-
agulant did not affect platelet function as measured by
response to ADP. Plasma b -TG was significantly higher
after CPB in animals that received only enoxaparin.
White cell counts increased during CPB in all groups;
there were no significant differences between groups. 
Bleeding times remained significantly prolonged for
more than 3 hours in all groups (Table I). In the enoxa-
parin group, however, bleeding times were still prolonged
at 24 hours despite full protamine neutralization.22,23
No wound hematomas or postprotamine wound
bleeding occurred in either the heparin or combination
groups. However, hematomas developed at cutdown
sites in 6 of 8 baboons in the enoxaparin group, 2 of
which required evacuation. 
Neutrophil elastase increased significantly during
CPB in all groups, and although 3-way MANOVA indi-
cated significant differences between groups, compar-
isons of each test group with the control group by 2-
way ANOVA were not significant (Table II). Similarly,
complement C3b/c also increased significantly during
CPB in all groups but did not increase further with pro-
tamine. Group differences were significant by 3-way
ANOVA but were not significantly different from the
control group by 2-way ANOVA. C4b/c, a marker for
the classic pathway, did not significantly change during
CPB in any group (Table II). 
By 3-way MANOVA both group and time effects and
the interaction of group and time were significant for
F1.2, TAT, and FPA (Table II). Enoxaparin significant-
ly inhibited the rise in prothrombin fragment F1.2,
TAT, and FPA during CPB as compared with control
animals (Figs 3, 4, and 5; Table II). The combination of
enoxaparin and heparin also attenuated the rise in these
markers, but only TAT concentrations were significant-
ly less than those measured in heparinized baboons.
After protamine, FPA increased nearly 19-fold in ani-
mals that were anticoagulated with enoxaparin, but nei-
ther TAT or F1.2 increased. This transitory rise in FPA
was not observed in other groups and did not persist in
the enoxaparin group.
Discussion
Both standard heparin and enoxaparin more com-
pletely inhibit FXa in baboon blood than in human
blood, but C1-s inhibition with heparin is greater in
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Fig 5. Blood fibrinopeptide-A before, during, and after CPB. Values are corrected for hematocrit. See Fig 2 for
an explanation of the symbols. 
human blood. Thus baboon data regarding thrombin
formation in this study should be relevant to clinical
CPB and cardiac operations at comparable levels of
anticoagulation. Neither anticoagulant alters activation
of complement or neutrophil elastase release in the pres-
ent baboon study. This observation differs from our ear-
lier in vitro study wherein enoxaparin, but not heparin,
suppressed both complement activation and elastase
release.7 As shown in the present study, suppression of
complement activation in human blood by enoxaparin
is not due to inhibition of C1s but may occur later in the
cascade. 
Complete suppression of thrombin generation during
cardiac operations offers prospects of significantly
reducing the thromboembolic and bleeding complica-
tions associated with these operations. Thrombin plays
a central role in the regulation of coagulation and also in
cell growth and migration.2 Thrombin directly activates
platelets, forms fibrin, and activates key coagulation
proteins (factors V, VIII, and XIII) but also activates
protein C and fibrinolysis.24 Although standard heparin
remains a prerequisite for CPB and cardiac surgery,
thrombin is progressively generated in both wound25
and perfusion circuit and circulates during extracorpo-
real perfusion.1 Several alternatives to heparin have
been investigated. These include coating perfusion cir-
cuits with ionic or covalently bound heparin,26,27 r-
hirudin,28 heparinoids,29 and inhibitors of factors IXa30
and Xa.7 None of these alternatives at the concentrations
used reduce the generation or activity of thrombin. In
contrast, enoxaparin attenuates thrombin formation and
activity in the baboon model of extracorporeal circula-
tion and in humans with deep vein thrombosis9; these
observations encourage efforts to reduce circulating
thrombin during cardiac operations. 
Because platelets express a thrombin receptor on
their external plasma membrane31 and are directly acti-
vated by thrombin, we expected to observe reduced
platelet adhesion and alpha granule release of b -TG in
animals anticoagulated with enoxaparin. This attenua-
tion of platelet activation did not occur and probably
reflects the fact that only small amounts of circulating
thrombin are sufficient to activate platelets or that other
agonists, such as ADP, contribute. Because the baboon
model does not produce increases in D-dimer and plas-
min-antiplasmin,13 fibrinolytic activity cannot be
assessed in this model.
Protamine does not fully reverse the anticoagulant
effect of enoxaparin and other low molecular weight
heparins,8,10,22,23 and further studies are needed to elu-
cidate the mechanism of this deficiency. In vitro 1:1
doses of protamine completely neutralize thrombin,22,23
but residual anti-factor Xa activity persists22 and is not
fully reversed by higher doses.23 In this in vivo study
with CPB, however, immediately after protamine, FPA
and b -TG significantly increase and platelet count
decreases only in animals anticoagulated with enoxa-
parin. Sixty minutes after protamine, plasma FPA con-
centrations are not significantly different from other
groups. By 24 hours, however, activated clotting times
do not differ from control animals, but a functional
deficiency of platelets remains and bleeding times are
prolonged. 
The increase in FPA levels with an accompanying
slight rise in plasma TAT or F1.2 concentrations sug-
gests a substantial increase in thrombin action with
marginally enhanced thrombin generation after prota-
mine. One explanation for this is that protamine prefer-
entially neutralizes the inhibitory effect of enoxaparin
on thrombin but not factor Xa.22 The increase in plas-
ma b -TG and the additional decline in platelet counts
immediately afterwards is consistent with platelet acti-
vation by thrombin but does not explain the elevated
bleeding times 24 hours later. Presence of thrombin-
activated partially degranulated platelets in circulation
may provide a partial explanation, but no continuing
stimulus for thrombin formation exists early after CPB
ends in the baboon model. Alternatively, direct inhibi-
tion of platelet function by enoxaparin or activation of
platelets by enoxaparin-protamine complexes that are
slowly cleared may interfere with platelet function and
prolong bleeding times. Our data do not explain the
mechanism of prolonged bleeding times 24 hours after
protamine. 
The failure to restore normal bleeding times after
CPB and late wound bleeding observed with enoxaparin
is consistent with clinical experience10-12 and negates
use of enoxaparin for cardiac operations. Nevertheless,
this study shows that a short-acting, quickly cleared, or
metabolized factor Xa inhibitor offers the prospect of
reducing thrombin formation and activity during open
cardiac surgery.
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